Soyoun Rachel Kim1, Basile Tessier Cloutier2, Samuel Leung3, Dawn Cochrane4, Heidi Britton4, Annick Pina5, Claudine Storness-Bliss1, David Farnell2, Leo Huang2, Kathryn Shum2, Amy Lum4, Janine Senz4, Cheng-Han Lee4, C Blake Gilks2, Lien Hoang2, Jessica N McAlpine6. 1. Department of Obstetrics and Gynecology, Division of Gynecology Oncology, University of British Columbia, Vancouver, BC, Canada. 2. Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada. 3. Genetic Pathology Evaluation Center, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada. 4. BC Cancer Agency, Vancouver, BC, Canada. 5. Department of Obstetrics and Gynecology, Division of Gynecology Oncology, Université de Montreal, Montreal, QC, Canada. 6. Department of Obstetrics and Gynecology, Division of Gynecology Oncology, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, Vancouver, BC, Canada. Electronic address: Jessica.Mcalpine@vch.ca.
Abstract
OBJECTIVE: Our aim was to characterize the pathological, molecular and clinical outcomes of clear cell carcinoma of the endometrium (CCC). METHODS: CCC underwent ProMisE (Proactive Molecular Risk Classifier for Endometrial Cancer) classification identifying four molecular subtypes: i) 'POLEmut' for ECs with pathogenic POLE mutations, ii) 'MMRd', if there is loss of mismatch repair proteins by immunohistochemistry (IHC), iii) 'p53wt' or iv) 'p53abn' based on p53 IHC staining. Clinicopathologic parameters, immune markers (CD3, CD8, CD79a, CD138, PD-1), ER, L1CAM, and outcomes were assessed. RESULTS: 52 CCCs were classified, including 1 (2%) POLEmut, 5 (10%) MMRd, 28 (54%) p53wt and 18 (35%) p53abn. Women with p53abn and p53wt CCCs were older than women with MMRd and POLEmut subtypes. p53wt CCC were distinct from typical p53wt endometrioid carcinomas; more likely to arise in older, thinner women, with advanced stage disease, LVSI and lymph node involvement, and a higher proportion ER negative, L1CAM overexpressing tumors with markedly worse outcomes. High levels of immune infiltrates (TILhigh) were observed in 75% of the CCC cohort. L1CAM overexpression was highest within p53abn and p53wt subtypes of CCC. CONCLUSION: CCC is a heterogeneous disease encompassing all four molecular subtypes and a wide range of clinical outcomes. Outcomes of patients with POLEmut, MMRd and p53abn CCC are not distinguishable from those of other patients with these respective subtypes of EC; p53wt CCC, however, differ from endometrioid p53wt EC in clinical, pathological, molecular features and outcomes. Thus, p53wt CCC of endometrium appear to be a distinct clinicopathological entity within the larger group of p53wt ECs.
OBJECTIVE: Our aim was to characterize the pathological, molecular and clinical outcomes of clear cell carcinoma of the endometrium (CCC). METHODS: CCC underwent ProMisE (Proactive Molecular Risk Classifier for Endometrial Cancer) classification identifying four molecular subtypes: i) 'POLEmut' for ECs with pathogenic POLE mutations, ii) 'MMRd', if there is loss of mismatch repair proteins by immunohistochemistry (IHC), iii) 'p53wt' or iv) 'p53abn' based on p53 IHC staining. Clinicopathologic parameters, immune markers (CD3, CD8, CD79a, CD138, PD-1), ER, L1CAM, and outcomes were assessed. RESULTS: 52 CCCs were classified, including 1 (2%) POLEmut, 5 (10%) MMRd, 28 (54%) p53wt and 18 (35%) p53abn. Women with p53abn and p53wt CCCs were older than women with MMRd and POLEmut subtypes. p53wt CCC were distinct from typical p53wt endometrioid carcinomas; more likely to arise in older, thinner women, with advanced stage disease, LVSI and lymph node involvement, and a higher proportion ER negative, L1CAM overexpressing tumors with markedly worse outcomes. High levels of immune infiltrates (TILhigh) were observed in 75% of the CCC cohort. L1CAM overexpression was highest within p53abn and p53wt subtypes of CCC. CONCLUSION: CCC is a heterogeneous disease encompassing all four molecular subtypes and a wide range of clinical outcomes. Outcomes of patients with POLEmut, MMRd and p53abn CCC are not distinguishable from those of other patients with these respective subtypes of EC; p53wt CCC, however, differ from endometrioid p53wt EC in clinical, pathological, molecular features and outcomes. Thus, p53wt CCC of endometrium appear to be a distinct clinicopathological entity within the larger group of p53wt ECs.
Authors: Antonio Travaglino; Antonio Raffone; Diego Raimondo; Damiano Arciuolo; Giuseppe Angelico; Michele Valente; Giulia Scaglione; Nicoletta D'alessandris; Paolo Casadio; Frediano Inzani; Antonio Mollo; Angela Santoro; Renato Seracchioli; Gian Franco Zannoni Journal: Int J Gynaecol Obstet Date: 2021-10-11 Impact factor: 4.447
Authors: Alice Bradfield; Lucy Button; Josephine Drury; Daniel C Green; Christopher J Hill; Dharani K Hapangama Journal: Methods Protoc Date: 2020-09-03
Authors: Marie Boennelycke; Elke E M Peters; Alicia Léon-Castillo; Vincent T H B M Smit; Tjalling Bosse; Ib Jarle Christensen; Gitte Ørtoft; Claus Høgdall; Estrid Høgdall Journal: Virchows Arch Date: 2021-06-11 Impact factor: 4.064
Authors: Lora H Ellenson; Britta Weigelt; Robert A Soslow; Amir Momeni-Boroujeni; Wissam Dahoud; Chad M Vanderbilt; Sarah Chiang; Rajmohan Murali; Eric V Rios-Doria; Kaled M Alektiar; Carol Aghajanian; Nadeem R Abu-Rustum; Marc Ladanyi Journal: Clin Cancer Res Date: 2021-02-18 Impact factor: 12.531
Authors: Arnaud Da Cruz Paula; Deborah F DeLair; Lorenzo Ferrando; Daniel J Fix; Robert A Soslow; Kay J Park; Sarah Chiang; Jorge S Reis-Filho; Ahmet Zehir; Mark T A Donoghue; Michelle Wu; David N Brown; Rajmohan Murali; Claire F Friedman; Dmitriy Zamarin; Vicky Makker; Jennifer J Mueller; Mario M Leitao; Nadeem R Abu-Rustum; Carol Aghajanian; Britta Weigelt Journal: Gynecol Oncol Date: 2021-02-21 Impact factor: 5.482